Literature DB >> 509349

Successful use of dantrolene sodium in human malignant hyperthermia syndrome: a case report.

C M Friesen, J B Brodsky, M F Dillingham.   

Abstract

We present a case of malignant hyperthermia in which successful management included the intravenous use of dantrolene sodium. A subsequent operation under spinal anaesthesia with oral dantrolene prophylaxis did not lead to development of malignant hyperthermia. Since this syndrome is rare during regional anaesthesia, the role of prophylactic oral dantrolene in preventing the redevelopment of malignant hyperthermia in our patient is open to question.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 509349     DOI: 10.1007/bf03006294

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


  5 in total

1.  A comparison of skeletal, cardiac, and smooth muscle actions of dantrolene sodium--a skeletal muscle relaxant.

Authors:  K O Ellis; J L Butterfield; F L Wessels; J F Carpenter
Journal:  Arch Int Pharmacodyn Ther       Date:  1976-11

2.  Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium.

Authors:  G G Harrison
Journal:  Br J Anaesth       Date:  1975-01       Impact factor: 9.166

3.  The prophylaxis of malignant hyperthermia by oral dantrolene sodium in swine.

Authors:  G G Harrison
Journal:  Br J Anaesth       Date:  1977-04       Impact factor: 9.166

4.  Evaluation of a muscle relaxant: dantrolene sodium (Dantrium).

Authors:  M H Dykes
Journal:  JAMA       Date:  1975-02-24       Impact factor: 56.272

5.  Dantrolene in porcine malignant hyperthermia.

Authors:  G A Gronert; J H Milde; R A Theye
Journal:  Anesthesiology       Date:  1976-06       Impact factor: 7.892

  5 in total
  5 in total

Review 1.  Dantrolene.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1984-01

Review 2.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

3.  Malignant hyperthermia: a possible new variant.

Authors:  D S Lee; J P Adams; J E Zimmerman
Journal:  Can Anaesth Soc J       Date:  1985-05

4.  The effect of dantrolene on skeletal-muscle sarcoplasmic-reticulum function in malignant hyperpyrexia in pigs.

Authors:  M D White; J G Collins; M A Denborough
Journal:  Biochem J       Date:  1983-05-15       Impact factor: 3.857

5.  Erythrocyte osmotic fragility testing and the prediction of canine malignant hyperthermia susceptibility.

Authors:  P H Cribb; E A Olfert; F B Reynolds
Journal:  Can Vet J       Date:  1986-12       Impact factor: 1.008

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.